SCHEDULE: State Street Reports 6% Stake in Cullinan Therapeutics

State Street Corporation has disclosed beneficial ownership of approximately 6% of Cullinan Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• State Street Corporation, through various subsidiaries, now beneficially owns 3,668,627 shares of Cullinan Therapeutics Inc. common stock.
• This represents approximately 6% of the total class of securities.
• The filing indicates shared voting power for 3,565,748 shares and shared disposition power for 3,668,627 shares.
• Sole voting and disposition power for State Street Corporation is reported as 0 shares.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on beneficial ownership changes without indicating significant shifts in investment strategy or company performance.

Positives

• State Street Corporation's increased beneficial ownership may signal confidence in Cullinan Therapeutics' long-term prospects.
• The filing provides transparency regarding significant institutional holdings.

Negatives

• The filing does not provide specific details on the strategy behind this ownership level, leaving room for speculation.
• The lack of sole voting or disposition power suggests a passive investment approach rather than active control.

Risks

• Potential for future changes in beneficial ownership by State Street Corporation could impact share price volatility.
• If State Street Corporation decides to divest its stake, it could lead to downward pressure on the stock price.

Future Outlook

This filing is primarily a disclosure of beneficial ownership and does not contain forward-looking statements or specific guidance from Cullinan Therapeutics Inc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant institutional holdings, as reported in Schedule 13G filings, are common in the biotechnology sector. Such filings provide insights into the investor base and potential stability of a company's stock.

Stakeholder Impact

• Shareholders: Increased institutional ownership can sometimes lead to greater stock liquidity and potentially more stable pricing, but also indicates a significant holder whose future actions could impact the price.
• Management of Cullinan Therapeutics Inc.: Awareness of significant institutional holders is important for investor relations and strategic planning.
• Potential Investors: The filing provides data points for assessing the company's ownership structure.

Next Steps

• State Street Corporation will continue to hold and potentially manage its beneficial ownership in Cullinan Therapeutics Inc.
• Cullinan Therapeutics Inc. will continue its operations, subject to market conditions and its own strategic initiatives.

Key Dates

Keywords

beneficial ownership, institutional investor, Schedule 13G, State Street Corporation, Cullinan Therapeutics, common stock, investment management